Toronto, Ontario – October 25, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that Dr. Lothar Lilge, Professor and Grad Student Coordinator, Medical Biophysics, University of Toronto, will be presenting Theralase’s anti-cancer technology at the Photodynamic Therapy and Photodiagnosis (“PDT-PDD”) Conference taking place from October 24 to 28, 2016, in Nancy, France.   Dr. Lilge will deliver an oral and poster presentation on “TLD-1433-Mediated Photo Dynamic Therapy as a Novel Intravesical Treatment for Bladder Cancer: in vitro, in vivo, and Good Laboratory Practice (“GLP”) Toxicology Validation”.   Urinary bladder cancer, which accounts for 3.3% of all cancers, is a socially significant healthcare problem that has become a major cause of morbidity, mortality, and health-related costs. Although first line treatments are … Read More

Toronto, Ontario – October 20, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that Health Canada has granted the Company Investigational Testing Authorization (“ITA”) approval to use its patent pending TLC-3200 Photo Dynamic Therapy (“PDT”) Laser System and TLC-3400 Dosimetry Fibre Optic Cage (“DFOC”) technology, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, to commence a Phase Ib clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”).   The TLC-3200 PDT Laser System delivers green laser light, at a wavelength of 525 nanometers (“nm”), while the DFOC technology precisely monitors the laser light to provide a uniform distribution of the laser light energy, in the correct dosage, to the bladder wall.   Theralase, possessing both … Read More

Toronto, Ontario – October 13, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has successfully demonstrated the ability of its lead Photo Dynamic Therapy (“PDT”) technology to increase survival by 575% for a very aggressive form of brain cancer, known as Glioblastoma Multiforme (“GBM”), in a rat model.   GBM, also known as glioblastoma and grade IV astrocytoma (malignant brain tumor made up of star-shaped cells), is the most common and most aggressive cancer that begins within the brain. GBM kills > 85% of those diagnosed within 5 years.   The National Cancer Institute (“NCI”) estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2015. It also estimates that … Read More

Toronto, Ontario – October 5, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today an update on the status of an Investigational Testing Authorization (“ITA”) filed with Health Canada for approval to use its patent pending TLC-3200 Photo Dynamic Therapy (“PDT”) Laser System and TLC-3400 Dosimetry Fibre Optic Cage (“DFOC”) technology, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, in a Phase Ib clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”). The TLC-3200 PDT Laser System delivers green laser light, at a wavelength of 525 nanometers (“nm”), while the DFOC technology precisely monitors the laser light to provide a uniform distribution of the laser light energy, in the correct dosage, to the bladder wall. Theralase … Read More

Toronto, Ontario – September 12, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the President and CEO of the Company, Roger Dumoulin-White, will present at 10:25 am on September 12, 2016 at the Rodman and Renshaw 18th Annual Global Investment Conference in New York City.   To view the webcast, please register at http://wsw.com/webcast/rrshq26/tltff   About Theralase Technologies Inc. Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules … Read More

Toronto, Ontario – Aug 29, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the six-month period ended June 30, 2016, total revenue increased from $677,817 to $893,138 from the same period in 2015, an 32% increase.   In Canada, revenue decreased 12% to $497,378 from $562,890, in the US, revenue increased 219% to $316,756 from $99,343 and international revenue increased 407% to $79,004 from $15,584. The decrease in Canadian revenue in 2H2016 and the corresponding increase in US and international revenue is attributable to the Company systematically building its sales and marketing teams in the Canadian and US market and the learning curves associated with training and developing a new sales force.   Now that the TLC-2000 is FDA … Read More

Toronto, Ontario – April 28, 2016, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on commercialization of medical devices to eliminate pain and development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has extended its Sponsored Research Agreement (“SRA”) with University Health Network (“UHN”), one of the top 5 cancer research institutes in the world. Under the terms of the SRA, Theralase and UHN will work together to evaluate Theralase’s patented and patent pending platform of novel Ruthenium (“Ru”) and Osmium (“Os”) based PDCs for new cancer indications, including: lung, melanoma and brain cancer. In addition, UHN will supply on-going scientific support to Theralase for Theralase’s submissions to the Food and Drug Administration (“FDA”) for approval of an Investigational New Drug (“IND”) application and will provide Theralase with scientific support for Health Canada and the FDA in approval of a … Read More

Toronto, Ontario – July 29, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has filed an Investigational Testing Authorization (“ITA”) with Health Canada for approval to use its patent pending TLC-3200 Photo Dynamic Therapy (“PDT”) Laser System and TLC-34XX Dosimetry Fibre Optic Cage (“DFOC”) technology, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, in a Phase Ib clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (“NMIBC”).   The TLC-3200 PDT Laser System delivers green laser light, at a wavelength of 525 nanometers (“nm”), while the DFOC technology precisely monitors the laser light to provide a uniform distribution of the laser light energy, in the correct dosage, to the bladder wall.   The clinical … Read More

Toronto, Ontario – June 22, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has filed a US patent for its proprietary Dosimetry Fibre Optic Cage (“DFOC”) technology. DFOC technology allows Theralase to precisely monitor and remotely control laser light energy delivered to hollow organs, such as the bladder, when undergoing treatment with Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”). The patent application is entitled, “Fiber Optic-Based Photodynamic Treatment Delivery and Irradiance Monitoring System and has been licenced to Theralase under a royalty agreement with Princess Margaret Cancer Centre, University Health Network (“UHN”).” The current methodology planned for the Phase Ib clinical study for NMIBC involves: ? Intravesical installation of … Read More

Toronto, Ontario – June 20, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has been granted a US patent for its lead anti-cancer drug, TLD-1433, by the United States Patent and Trademark Office (“USPTO”). US patent number 9,345,769 (filed on April 15, 2013 and issued on May 24, 2016) provides patent protection for tens of thousands of metal based PDCs; including, Theralase’s lead anti-cancer drug, TLD-1433, currently under investigation by the Company for the destruction of Non-Muscle Invasive Bladder Cancer (“NMIBC”). The US patent provides patent protection for Theralase’s second major platform of anti-cancer PDCs for twenty years from date of filing, plus an allowable extension of 433 days, providing a minimum patent protection in the US of TLD-1433 … Read More